LON:ETX e-therapeutics (ETX) Share Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free ETX Stock Alerts GBX 9.78 -0.10 (-1.01%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range 9.24▼ 10.2950-Day Range 8.66▼ 16.3552-Week Range 8▼ 24Volume3.08 million shsAverage Volume675,271 shsMarket Capitalization£57.12 millionP/E RatioN/ADividend Yield3.35%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get e-therapeutics alerts: Email Address Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About e-therapeutics Stock (LON:ETX)e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.Read More ETX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETX Stock News HeadlinesApril 26, 2024 | americanbankingnews.come-therapeutics (LON:ETX) Stock Price Crosses Below 200 Day Moving Average of $11.85April 20, 2024 | lse.co.ukE-therapeutics Share ChatMay 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 11, 2024 | msn.comEliem Therapeutics to buy Tenet, announces $120 million private placementApril 10, 2024 | seekingalpha.comAquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024April 10, 2024 | lse.co.uke-Therapeutics says company faces lack of interest as UK listingApril 10, 2024 | marketwatch.come-Therapeutics Shares Fall on London Delisting Plan; Mulls Move to New YorkApril 10, 2024 | msn.com‘Lack of appetite’ in London drives another high-tech firm to NasdaqMay 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 10, 2024 | msn.comDrug discovery firm e-therapeutics to quit London Stock Exchange following £29m fundraiseMarch 16, 2024 | msn.comAquestive maps out FDA approval for sublingual anaphylaxis drugJanuary 3, 2024 | finance.yahoo.comWe're Hopeful That e-therapeutics (LON:ETX) Will Use Its Cash WiselyDecember 27, 2023 | msn.comMedical innovator e-therapeutics to stop trading on US-based marketNovember 13, 2023 | markets.businessinsider.comEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discoveryOctober 30, 2023 | businesswire.comEvecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot EhrichOctober 26, 2023 | proactiveinvestors.comE-therapeutics bolsters generative AI integration and strategic...September 28, 2023 | benzinga.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 28, 2023 | marketwatch.comQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldSeptember 20, 2023 | proactiveinvestors.come-therapeutics appoints new CFOJuly 13, 2023 | uk.finance.yahoo.comETX.L - e-Therapeutics plcJune 8, 2023 | wsj.comElicio Therapeutics Inc.May 23, 2023 | businesswire.comAgeX Therapeutics Announces Appeal of NYSE American DeterminationMay 10, 2023 | businesswire.comRapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian MarketMay 10, 2023 | marketwatch.comDelix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001May 6, 2023 | marketwatch.comAcute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,PfizerMay 4, 2023 | marketwatch.comE-Therapeutics FY 2023 Pretax Loss Widened on Higher R&D CostsMay 4, 2023 | finance.yahoo.come-Therapeutics working to capitalise on AI "blindside"See More Headlines Receive ETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/17/2020Today5/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ETX CUSIPN/A CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-10,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.75% Return on Assets-29.10% Debt Debt-to-Equity Ratio0.33 Current Ratio22.20 Quick Ratio20.13 Sales & Book Value Annual Sales£295,000.00 Price / Sales193.13 Cash FlowGBX 1.92 per share Price / Cash Flow5.07 Book ValueGBX 5 per share Price / Book1.95Miscellaneous Outstanding Shares584,330,000Free FloatN/AMarket Cap£56.97 million OptionableNot Optionable Beta0.48 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Ahmad Ali Mortazavi (Age 53)CEO & Director Comp: $270kMr. Timothy BrethertonCFO, Director of Finance & Operations and Company SecretaryDr. Laura Roca-Alonso Ph.D.Chief Operating & Business OfficerMr. Alan Whitmore B.Sc.Ph.D., Chief Scientific OfficerMr. Ankit SharmaHead of Software EngineeringMr. Graham CraggsHead of Therapeutic DiscoveryMore ExecutivesKey CompetitorsRedx PharmaLON:REDXPoolbeg PharmaLON:POLBOpen OrphanLON:ORPHTissue Regenix GroupLON:TRXArecor TherapeuticsLON:ARECView All CompetitorsInsidersTrevor Mervyn JonesBought 91,325 shares on 1/9/2024Total: £730,600.00 ($8.00/share)Trevor Mervyn JonesBought 34,830 shares on 7/6/2023Total: £766,260.00 ($22.00/share)View All Insider Transactions ETX Stock Analysis - Frequently Asked Questions How have ETX shares performed in 2024? e-therapeutics' stock was trading at GBX 8.24 at the beginning of the year. Since then, ETX stock has increased by 18.3% and is now trading at GBX 9.75. View the best growth stocks for 2024 here. How were e-therapeutics' earnings last quarter? e-therapeutics plc (LON:ETX) posted its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.03. What other stocks do shareholders of e-therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY). How do I buy shares of e-therapeutics? Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ETX) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlace😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
